» Articles » PMID: 37936881

Using the RE-AIM Framework to Assess National Teledermatology Expansion

Overview
Specialty Health Services
Date 2023 Nov 8
PMID 37936881
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Teledermatology has been utilized in the United States Department of Veterans Affairs (VA) for decades but continues to have incomplete penetration. VA has funded an initiative to enhance access to dermatology services since 2017 to support asynchronous teledermatology for Veterans living in rural areas. As part of an ongoing evaluation of this program, we assessed the teledermatology activity between the fiscal years 2020 and 2022. We focused on the second cohort of the initiative, comprising six VA facilities and their 54 referral clinics.

Methods: We studied teledermatology programs at cohort facilities using the reach, effectiveness, adoption, implementation, and maintenance framework. We used a mixed-methods design including annual online reports completed by participating facilities and VA administrative data. When possible, we compared the data from the 3 years of teledermatology funding with the baseline year prior to the start of funding.

Findings: Reach: Compared with the baseline year, there was a 100% increase in encounters and a 62% increase in patients seen at the funded facilities. Over 500 clinicians and support staff members were trained. Effectiveness: In FY 2022, primary or specialty care clinics affiliated with the funded facilities had more dermatology programs than primary or specialty care clinics across the VA (83% vs. 71% of sites). Adoption: By the end of the funding period, teledermatology constituted 16% of dermatology encounters at the funded facilities compared with 12% nationally. This reflected an increase from 9.2% at the funded facilities and 10.3% nationally prior to the funding period. Implementation: The continued funding for staff and equipment facilitated the expansion to rural areas. Maintenance: By the end of the funding period, all facilities indicated that they had fully implemented their program for patients of targeted primary care providers. The Program Sustainability Index scores generally increased during the funding period.

Conclusions: Targeted funding to support asynchronous teledermatology implementation for rural Veterans increased its reach, adoption, and implementation, ultimately improving access. Providing program guidance with staffing and training resources can increase the impact of these programs. Ongoing efforts to maintain and increase communication between primary care and dermatology will be needed to sustain success.

Citing Articles

RE-AIM for rural health innovations: perceptions of (mis) alignment between the RE-AIM framework and evaluation reporting in the Department of Veterans Affairs Enterprise-Wide Initiatives program.

Chasco E, Van Tiem J, Johnson N, Balkenende E, Steffen M, Jones D Front Health Serv. 2024; 4:1278209.

PMID: 38655394 PMC: 11035780. DOI: 10.3389/frhs.2024.1278209.

References
1.
Wang R, Barbieri J, Nguyen H, Stavert R, Forman H, Bolognia J . Clinical effectiveness and cost-effectiveness of teledermatology: Where are we now, and what are the barriers to adoption?. J Am Acad Dermatol. 2020; 83(1):299-307. PMC: 7302990. DOI: 10.1016/j.jaad.2020.01.065. View

2.
Landow S, Oh D, Weinstock M . Teledermatology Within the Veterans Health Administration, 2002-2014. Telemed J E Health. 2015; 21(10):769-73. DOI: 10.1089/tmj.2014.0225. View

3.
Boyers L, Schultz A, Baceviciene R, Blaney S, Marvi N, Dellavalle R . Teledermatology as an educational tool for teaching dermatology to residents and medical students. Telemed J E Health. 2015; 21(4):312-4. PMC: 4378857. DOI: 10.1089/tmj.2014.0101. View

4.
Darkins A . The growth of telehealth services in the Veterans Health Administration between 1994 and 2014: a study in the diffusion of innovation. Telemed J E Health. 2014; 20(9):761-8. DOI: 10.1089/tmj.2014.0143. View

5.
Yeboah C, Harvey N, Krishnan R, Lipoff J . The Impact of COVID-19 on Teledermatology: A Review. Dermatol Clin. 2021; 39(4):599-608. PMC: 8162710. DOI: 10.1016/j.det.2021.05.007. View